Evidence map›Paper›PMID 26526896›Full record

ArticleSpinal cord2016

Co-transplantation of autologous bone marrow mesenchymal stem cells and Schwann cells through cerebral spinal fluid for the treatment of patients with chronic spinal cord injury: safety and possible outcome.

S Oraee-Yazdani, M Hafizi, A Atashi, F Ashrafi, A-S Seddighi, S M Hashemi, A Seddighi, M Soleimani, A Zali

Open access · bronzeAbstract readCase Reports
PubMed Publisher
In one paragraph

Article in Spinal cord, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 5 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 5 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

S Oraee-YazdaniFunctional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
M HafiziDepartment of Stem Cell Biology, Stem Cell Technology Research Center, Tehran, Iran.
A AtashiDepartment of Stem Cell Biology, Stem Cell Technology Research Center, Tehran, Iran.
F AshrafiFunctional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
A-S SeddighiFunctional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
S M HashemiDepartment of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
A SeddighiFunctional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
M SoleimaniDepartment of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
A ZaliFunctional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IRStem Cell Technology Research Center · IRTarbiat Modares University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

STUDY

designThis is a clinical trial (phase 1).

objectivesThe objective of this study was to asses the safety and feasibility of bone marrow mesenchymal stem cell (MSC) and Schwann cell (SC) co-injection through cerebral spinal fluid (CSF) for the treatment of patients with chronic spinal cord injury.

methodsSix subjects with complete spinal cord injury due to trauma according to International Standard of Neurological Classification for Spinal Cord Injury (ISNCSCI) developed by the American Spinal Injury Association were enrolled. They received autologous co-transplantation of MSC and SC through lumbar puncture. Neurological status of the patients was determined by ISNCSCI, as well as by assessment of functional status by Spinal Cord Independent Measure. Before and after cell transplantation, magnetic resonance imaging (MRI) was performed for all the patients. Before the procedure, all the patients underwent electromyography, urodynamic study (UDS) and MRI tractograghy. After transplantation, these assessments were performed in special cases when the patients reported any changes in motor function or any changes in urinary sensation.

resultsOver the mean 30 months of follow-up, the radiological findings were unchanged without any evidence of neoplastic tissue overgrowth. American Spinal Injury Association class in one patient was changed from A to B, in addition to the improvement in indexes of UDS, especially bladder compliance, which was congruous with axonal regeneration detected in MRI tractography. No motor score improvement was observed among the patients.

conclusionNo adverse findings were detected at a mean of 30 months after autologous transplantation of the combination of MSCs and SCs through CSF. It may suggest the safety of this combination of cells for spinal cord regeneration.

Indexed as

Spinal Cord RegenerationAdultCerebrospinal FluidChronic DiseaseCombined Modality TherapyFeasibility StudiesFemaleHumansMaleMesenchymal Stem Cell TransplantationMiddle AgedSchwann CellsSpinal Cord InjuriesTransplantation, AutologousTreatment Outcome

Identifiers

PMID26526896
OpenAlexW2212805166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.